Oramed Pharmaceuticals Inc. Q1 2026 Financial Results: Key Developments, Strategic Investments, and Shareholder Considerations
Summary of Key Points
- Quarter Ended: March 31, 2026
- Common Shares Outstanding: 40,926,081 (as of May 19, 2026)
- Stock Listings: Nasdaq Capital Market (ORMP), Tel Aviv Stock Exchange
- Filer Status: Non-accelerated filer, Smaller reporting company, Not an emerging growth company
- Not a Shell Company: Confirmed
Financial Highlights
- Net Income (Q1 2026): \$38,310,000
- Basic Earnings Per Share: \$0.94
- Diluted Earnings Per Share: \$0.91
- Net Loss (Q1 2025 for comparison): (\$7,642,000)
- Total Stockholders’ Equity (March 31, 2026): \$238,276,000
- Total Stockholders’ Equity (March 31, 2025): \$139,894,000
- Cash and Cash Equivalents (March 31, 2026): \$11,025,000
- Investments at Fair Value (March 31, 2026): \$36,576,000
- Investment in Lifeward (March 31, 2026): \$22,492,000
- Investment in Real Estate (March 31, 2026): \$71,623,000
- Marketable Securities (March 31, 2026): \$4,965,000
Significant and Potentially Price-Sensitive Developments
1. Exceptional Net Profit Driven by Lifeward Transaction
Oramed posted a net profit of \$38.3 million for the first quarter of 2026, a significant turnaround from a net loss of \$7.6 million in the same quarter last year. This strong financial performance was largely driven by a capital gain from the sale of intellectual property related to its POD™ technology platform to Lifeward. This transaction resulted in a one-time gain that substantially boosted the company’s earnings for the period.
The Lifeward deal is not only a major source of immediate profit but also leaves Oramed with a substantial investment in Lifeward, valued at \$22.5 million as of March 31, 2026. The company has classified this as an investment in a variable interest entity (VIE) for which Oramed is not the primary beneficiary, thus not consolidating Lifeward’s results into its own.
2. Shift in Business Focus: Real Estate and Marketable Securities
Oramed is actively diversifying its portfolio. The company’s real estate investments have grown to \$71.6 million, and its investments in marketable securities and other equity holdings (including positions in companies such as IC Hotels, Entera Bio, Nano Dimension, and Pelthos Therapeutics) total nearly \$5 million. The company cautions that these investments come with significant risks and may not yield the anticipated long-term value appreciation or income streams.
In addition, Oramed maintains exposure to derivative instruments (put and call options), primarily on Nano Dimension shares, which could introduce volatility into future earnings.
3. Exposure to Ruby Capital Investment Fund Sapphire II
Oramed has invested in the Ruby Capital Investment Fund Sapphire II, Limited Partnership. This position carries risks including illiquidity, capital call obligations, uncertainty regarding the timing and amount of any returns, and the potential loss of invested capital.
4. Research and Development Outlook
Through its subsidiary Oratech, Oramed is continuing research and development activities, including clinical and preclinical trials. The company has outlined plans for trial enrollment, data collection, and analysis timelines, with results and their impact on future strategy pending.
5. Foreign Currency and Litigation Risks
The company notes exposure to foreign currency exchange rate fluctuations, primarily related to the Israeli Shekel, which may impact operating expenses, financial results, and cash flows. There is also a caution regarding potential litigation risks.
Forward-Looking Statements and Risk Factors
Oramed’s management emphasizes that the company’s outlook for future periods is subject to uncertainties, including the performance of its investments, success of its real estate ventures, and ongoing development projects. Historical research and trial outcomes do not guarantee future results.
Risk factors specifically highlighted include:
- Potential failure to achieve expected returns on real estate and marketable securities
- Risks associated with the Lifeward transaction and future dealings with Lifeward
- Ongoing R&D uncertainties and regulatory timelines
- Exposure to litigation and foreign exchange fluctuations
- Risks related to investments in illiquid funds and derivative instruments
Shareholder Considerations
- The Lifeward transaction is likely to be price-sensitive: The one-time profit dramatically improves this quarter’s earnings, but investors should be aware this is non-recurring and future quarters may not reflect similar profitability unless further deals are struck.
- Increased focus on real estate and marketable securities: This may signal a strategic shift away from the company’s traditional biotech/pharmaceutical operations. Shareholders should carefully consider the associated risks and potential for value creation or loss.
- Large cash and investment balances: The strong balance sheet provides the company with flexibility for future investments or operational pivots, but also introduces exposure to market risk and potential capital losses.
- Potential volatility: The company’s increasing use of derivatives and investments in illiquid assets could create future earnings volatility, both positive and negative.
Conclusion
Oramed Pharmaceuticals delivered a remarkable quarterly profit, primarily due to the Lifeward transaction. However, the company’s evolving focus on real estate and financial investments marks a departure from its historical core operations. Investors should weigh the risks and opportunities associated with this new direction, and recognize that the recent profit surge may not be sustainable.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should review the company’s full filings and consult with financial advisors before making investment decisions.
